Last reviewed · How we verify
BRL 49653C — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
BRL 49653C (BRL 49653C) — National Taiwan University Hospital. BRL 49653C is a drug that has been investigated for its potential therapeutic effects.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BRL 49653C TARGET | BRL 49653C | National Taiwan University Hospital | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BRL 49653C CI watch — RSS
- BRL 49653C CI watch — Atom
- BRL 49653C CI watch — JSON
- BRL 49653C alone — RSS
Cite this brief
Drug Landscape (2026). BRL 49653C — Competitive Intelligence Brief. https://druglandscape.com/ci/brl-49653c. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab